Cargando...
Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab
BACKGROUND: Pertuzumab disrupts heterodimerization between human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), HER3, and HER4. Thus, pertuzumab could result in adverse events similar to those observed with EGFR antagonists, such as diarrhea. We report the inc...
Gardado en:
| Publicado en: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Oxford University Press
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5834072/ https://ncbi.nlm.nih.gov/pubmed/28057664 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdw695 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|